Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc. (DRUG.CN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
drug.cn · pe ratio · data through Sep 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Bright Minds Biosciences Inc. (DRUG.CN) measures how much investors pay for each dollar of the company's trailing earnings. DRUG.CN's current PE ratio of N/A is calculated by dividing its stock price of $96.12 by its TTM earnings per share of -$2.87.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-09-30
PE Ratio History
2019 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Bright Minds Biosciences Inc.You DRUG.CN | $746M | N/A | — | -$2.87 |
 Cresco Labs Inc. CL.CN | $453M | N/A | — | -$0.40 |
 Spectral Medical Inc. EDT.TO | $405M | N/A | — | -$0.17 |
 Eupraxia Pharmaceuticals Inc. EPRX.TO | $305M | N/A | — | -$0.98 |
 Fennec Pharmaceuticals Inc. FRX.TO | $356M | N/A | — | -$0.36 |
 Knight Therapeutics Inc. GUD.TO | $892M | N/A | — | -$0.05 |
 High Tide Inc. HITI.V | $289M | N/A | — | -$0.62 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-09-30Latest FY2025 | — | $-1.78 | — | |
2024-09-30 FY2024 | — | $-0.65 | — | |
2023-09-30 FY2023 | — | $-1.98 | — | |
2022-09-30 FY2022 | — | $-6.15 | — | |
2021-09-30 FY2021 | — | $-4.74 | — | |
2020-09-30 FY2020 | — | $-0.38 | — | |
2019-09-30 FY2019 | — | $-0.06 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Bright Minds Biosciences Inc. (DRUG.CN) measures how much investors pay for each dollar of the company's trailing earnings. DRUG.CN's current PE ratio of N/A is calculated by dividing its stock price of $96.12 by its TTM earnings per share of -$2.87.
Frequently asked questions
DRUG.CN pe ratio · 6 questionsDRUG.CN's current PE ratio is N/A as of 2026-06-08, based on a stock price of $96.12 and TTM EPS of -$2.87. Data sourced from Financial Modeling Prep via DRUG.CN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Bright Minds Biosciences Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08